English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary   Background  Irritable bowel syndrome with constipation ( IBS ‐C) represents a significant burden to patients and healthcare systems due to its prevalence and lack of successful symptomatic resolution with established treatment options. Linaclotide 290 μg has recently been approved by the European Medicines Agency ( EMA ) for moderate‐to‐severe  IBS ‐C and by the  US  Food and Drug Administration for  IBS ‐C (290 μg dose) and for chronic constipation (145 μg dose).    Aim  To summarise data leading to the approval of linaclotide for  IBS ‐C, with focus on  EMA ‐pre‐specified outcome measures.    Methods  Literature search of a peer‐review database (PubMed) and review of congress abstracts on linaclotide preclinical and clinical trial data in  IBS ‐C.    Results  Preclinical studies suggest that the guanylate cyclase C agonist (GCCA) linaclotide acts through elevation of cyclic guanosine monophosphate (cGMP) levels, leading to accelerated gastrointestinal (GI) transit through increased fluid secretion and reduced visceral hypersensitivity. Clinical trial data demonstrate that linaclotide improves abdominal symptoms (pain, bloating) and bowel symptoms (constipation) compared with placebo in patients with IBS‐C. The most frequent side effect, diarrhoea, results from the therapeutic action of linaclotide. Linaclotide acts locally in the GI tract with minimal systemic exposure, resulting in low oral bioavailability and thus a low risk of relevant systemic adverse effects.    Conclusion  Linaclotide, a first‐in‐class  GCCA , is a promising new drug with a novel, dual mechanism of action that, unlike more well‐established agents, can relieve the abdominal pain, bloating and constipation associated with  IBS ‐C and has a low propensity for systemic side effects.

Review article: linaclotide for the management of irritable bowel syndrome with constipation